Company: IMRX
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001790340-25-000104
Chunk: 341

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 341
---
 available for evaluation by the Chief Operating Decision Maker ("CODM") in making decisions, including regarding resource allocation and assessing performance. The Company’s Chief Executive Officer is its CODM.The Company's CODM uses consolidated single-segment financial information for purposes of: allocating resources, evaluating performance, making operating decisions, setting incentive targets, and planning and forecasting for future periods. The Company's CODM makes such decisions based on consolidated net loss. This measure is used to monitor budget versus actual results to evaluate the performance of the segment. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to deploy these resources across functions and operations (including research and development) that align with the Company’s strategic goals. All of the Company’s long-lived assets are held in the United States.The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment.Three Months Ended June 30,Six Months Ended June 30,2025202420252024Program expenses(1)atebimetinib (IMM-1-104)$5,169,330 $3,807,470 $9,427,266 $7,453,630 IMM-6-415278,612 1,132,376 1,902,367 2,159,946 Other programs1,172,927 1,483,901 2,415,035 3,534,513 Non-program expenses(2)1,583,015 1,535,804 2,787,399 2,843,168 Employee-related costs4,944,540 5,201,914 10,323,479 10,930,991 Stock-based compensation expense1,524,943 1,661,749 3,217,210 3,136,507 Depreciation and amortization84,527 90,533 169,788 180,742 Other segment items(3)(324,013)(833,820)(762,532)(1,851,741)Net loss$14,433,881 $14,079,927 $29,480,012 $28,387,756 (1) Includes direct research and development expenses.(2) Includes general and administrative expenses, in addition to facilities and other research and development expenses.(3) Includes interest income and other (income) expense.

22